BIO-key International (NASDAQ: NASDAQ:BKYI) reported an increase in revenue and a substantial reduction in net loss for the third quarter of 2024 during its earnings call on November 15. The company, a provider of biometric software and hardware solutions, saw its revenue rise by 18% to $2.1 million compared to the same quarter in the previous year, with high-margin license revenue jumping 52% to $1.4 million.
Despite a decrease in total revenues for the first nine months of 2024, BIO-key improved its net loss to $0.7 million, down from $1.8 million in Q3 2023, and reported a net income of $2.9 million, or $1.69 per share. The company also secured significant orders from a foreign defense ministry and a major financial services customer, which are expected to impact future results positively.
Key Takeaways
- BIO-key's revenue increased to $2.1 million in Q3 2024, an 18% rise year-over-year.
- High-margin license revenue grew significantly by 52% to $1.4 million.
- A major order worth $910,000 from a financial services customer will be recognized partially in Q4 2024 and Q1 2025.
- The company reported a net income of $2.9 million, or $1.69 per share.
- BIO-key anticipates 2024 annual revenues to meet or exceed the previous year's $7.75 million.
- Gross margins improved and are expected to remain around 70%.
- Operating expenses were reduced, and the company aims for breakeven and profitability by 2025.
Company Outlook
- BIO-key aims to enhance revenue and achieve profitability by focusing on subscription revenue and expanding its presence on the AWS Marketplace.
- The company forecasts a breakeven and profitability by 2025, with a continued focus on increasing high-margin license revenue.
- Gross margins are expected to stay in the 70% range, contributing to a quicker path to profitability.
Bearish Highlights
- Total (EPA:TTEF) revenues for the first nine months of 2024 were down to $5.5 million from $5.9 million in the same period of 2023.
Bullish Highlights
- The company secured a $500,000 contract from an international defense ministry.
- A $910,000 order from a financial services customer is expected to contribute significantly to future revenues.
- A large international project is expected to generate at least $2.4 million in Q4 2024.
Misses
- The company exited a low-margin civil agreement in Europe, which contributed to the revenue decrease over the nine months of 2024.
Q&A highlights
- No questions were asked during the call, indicating potentially clear communication of the company's status and outlook.
BIO-key International's Q3 2024 earnings call presented a company on the cusp of a financial turnaround, with significant orders and strategic shifts promising a brighter future. The company's exit from a low-margin service agreement and focus on high-margin solutions like PortalGuard suggest a deliberate move toward more profitable ventures. With most of the $1.9 million in accounts receivable already collected and minimal impact from financing costs on Q4 expenses, BIO-key appears to be managing its finances effectively. The upcoming Gartner (NYSE:IT) IAM conference in December and the invitation for ongoing communication through their investor relations team demonstrate BIO-key's commitment to transparency and stakeholder engagement.
InvestingPro Insights
BIO-key International's recent earnings report shows promising signs of financial improvement, but InvestingPro data reveals some underlying challenges. The company's market cap stands at a modest $1.86 million, reflecting its current position as a small-cap player in the biometric solutions market.
An InvestingPro Tip indicates that BIO-key is "quickly burning through cash," which aligns with the company's focus on achieving breakeven and profitability by 2025. This cash burn rate underscores the importance of the recent high-value contracts and the shift towards high-margin license revenue mentioned in the earnings call.
Another relevant InvestingPro Tip notes that the "stock has taken a big hit over the last week," with a 1-week price total return of -12.07%. This recent downturn contrasts with the positive narrative from the earnings report, suggesting that market sentiment may not yet fully reflect the company's reported improvements.
Despite the recent stock performance, BIO-key's revenue for the last twelve months as of Q2 2024 was $6.96 million, which is close to the company's anticipated 2024 annual revenue of at least $7.75 million. However, the revenue growth rate of -3.86% over the same period indicates ongoing challenges in expanding the top line.
For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and metrics that could provide deeper insights into BIO-key's financial health and market position. Currently, there are 14 additional InvestingPro Tips available for BKYI, which could be valuable for those looking to make informed investment decisions.
Full transcript - BIO-Key International Inc (BKYI) Q3 2024:
Operator: Good morning, everyone. Thank you for standing by, and welcome to Biokey International's 2024 Third Quarter Conference Call. During management's prepared remarks, all participants will be in listen-only mode. Afterwards, listeners will be invited to participate in a question and answer session. As a reminder, this conference is being recorded today, Friday, November 15, 2024. I will now turn the call over to Bill Jones, Investor Relations. You may proceed.
Bill Jones: Thank you, Wyatt. Our host today is Biokey's Chairman and CEO, Mike DePasquale, and its CFO, Ceci Welch.
Mike DePasquale: As a reminder, today's conference call and webcast and answers to investor questions include forward-looking statements, which are subject to certain risks and uncertainties that may cause actual realized results to differ materially from those currently expected. Words such as anticipate, believe, estimate, expect, plan, and project, or similar words, typically express and identify forward-looking statements. These statements are made based on management's beliefs and assumptions, using information currently available as of today, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For a complete description of these and other risks that may affect future performance of the company, please see risk factors in the company's annual report as filed on Form 10-K with the SEC. Listeners are also cautioned not to place undue reliance on forward-looking statements, which speak only as of today. BioKey undertakes no obligation to revise or disclose any revisions to these statements to reflect circumstances or events that may occur after today. Now I will hand the call over to Mike to begin. Mike?
Mike DePasquale: Thanks, Bill. Good morning, and thank you all for joining today's call. After my prepared remarks, I will turn the call over to Ceci for a brief financial overview, and then we will open the call to investor questions. BIO-key reported a solid Q3 performance with revenue increasing 18% compared to Q3 last year, to $2.1 million, which is a $1 million improvement sequentially from last quarter. Importantly, high-margin license revenue rose 52% to $1.4 million in Q3 2024, which is a significant improvement. We also received, subsequent to the close of the quarter, a number of large orders, one from a leading foreign defense ministry, as well as the province of British Columbia and Williamsburg, Virginia. Again, as I mentioned, after the quarter end, we closed a large order from a long-time foreign banking and financial service customer for secure in-person identity, a portion of which will be reflected in this quarter or Q4 results and the balance in 2025. This customer has utilized BioKey technology to enroll the biometrics of more than 25 million of its banking customers over the past few years as part of their Know Your Customer (KYC) process, and they have been using our fingerprint technology to verify customer identities against the bank card, account number, or ID number prior to processing any transactions. They are now in the process of upgrading its system to BIO-key's far more robust fingerprint-only ID solution, which allows them to positively identify the customer by matching solely their fingerprint against the biometric record securely stored in the cloud. This, what we call one-to-many matching solution, requires greater sophistication and IT resources than matching a biometric to a known account or ID number. As a result, the customer plans to host our solution entirely on the Amazon (NASDAQ:AMZN) Web Services (AWS) infrastructure to support the substantial technical demands of real-time one-to-many biometric ID. The customer is deploying our enhanced solution utilizing the full benefit of our industry-leading biometric authentication technology to provide greater customer security, reduce fraudulent transactions, and enhance the customer experience as well as staff productivity by trimming transaction times by approximately 30 seconds. If you think about it, 30 seconds per transaction over millions of transactions is a lot of time savings. We believe this is a very exciting example of the power and efficiency of our biometric solutions to create transformational business and customer benefits. We plan to work with our customer and AWS, our partner, to develop a white paper or case study on this deployment. Our advanced biometric solutions can bring to large-scale enterprise or government customers. We did have a few other large orders from existing customers received in September from one of the world's most respected and tech-savvy defense ministries. The orders were pursuant to a three-year purchasing agreement under which the Defense Ministry has steadily expanded its deployment of BIO-key solutions into new programs and user scenarios, allowing for secure, boneless, tokenless, and passwordless authentication access to digital services. The deployment now encompasses over 33,000 users, and we expect additional awards as the ministry expands the scope of our solutions to additional personnel. Likewise, as I mentioned, the province of British Columbia is adding 10,000 users to their existing deployment of our Web Key software, which is integrated with Broadcom (NASDAQ:AVGO)'s SiteMinder infrastructure to streamline and strengthen secure biometric access to applications via SAML 2 federation standards. British Columbia is at the forefront of using biometric authentication for roving user scenarios that require advanced security, which is where we really excel. Our biometric solutions also reduce the cost and risks of what you have solutions that only verify that a card token, even a password, is present, but not necessarily with the authorized user. In terms of business development, I want to highlight the recent availability of our PortalGuard iDesk platform on Amazon Web Services or the AWS Marketplace, which enables Amazon customers around the world to purchase and deploy Portal Guard within their enterprise. Over 300,000 active customers find, test, buy, and deploy software solutions on the AWS marketplace. BioKey's position on AWS expands our visibility and reach into the community's substantial base of customer prospects. Though we are still in the early days and just starting to roll out marketing initiatives, we have been meeting with the Amazon sellers and partners to support this opportunity. We have already begun to source initial interest and product inquiries. The continued trend of remote work environments is likely a permanent fixture, and additional regulatory requirements are increasing stringent cybersecurity underwriting standards, and they are mandating enhanced security solutions such as multi-factor authentication for employees, partners, and customers that access business systems and data, which are exactly the problems that BioKey Solutions address. As with most small public companies, our performance varies on a quarter-to-quarter basis, mainly due to the timing and impact of larger customer contracts. Importantly, we are building a growing base of high-margin annual recurring revenues or ARRs with solid expansion potential. We will also continue to evaluate potential strategic opportunities to leverage our core expertise, products, and assets to create value for shareholders. We believe that the value of our technology, products, and our customer base with annual recurring revenues of approximately $6 million has a strategic value that significantly exceeds our current market cap. Today, millions of people use factor authentication solutions on a daily basis for secure access to a variety of mobile and web applications, on-premise and in the cloud, from all of their devices. At BioKey, we go beyond just passwordless. We offer phoneless and tokenless authentication methods, which is a critical differentiator for retail, call centers, shop floor, and healthcare environments where roving workers use shared workstations. We remain very encouraged by the growing enterprise awareness of the importance of implementing secure zero-trust identity and access management solutions, which is really the core of our business offerings. We remain focused on driving revenue growth and progressing our business to the point of profitability and positive cash flow over the coming quarters. We will support and leverage our channel alliance partners around the globe while also working to progress larger-scale customer dialogues via our in-house direct sales efforts, domestically. Turning to our balance sheet, we were successful in improving our cash position in Q3 with approximately $1.9 million in gross proceeds from a warrant inducement agreement with an existing holder of BIO-key warrants. The investor exercised warrants to purchase over one million shares of BioKey's common stock at an amended exercise price of $1.85 and received Series A and Series B warrants to purchase additional shares also at $1.85. With that, let me turn the call to Cece to review financials before we take questions. Thank you, Mike.
Ceci Welch: As you know, we issued our earnings release and filed our 10-Q last evening. So let me review some of the highlights, keeping in mind that our year-over-year comparisons are to the restated 2023 results, as filed in our Form 10-K. BioKey's revenues increased 18% to $2.1 million in Q3 2024 from $1.8 million in Q3 2023 and $1.1 million in Q2 2024. The increase is driven by higher software license fees and hardware revenue as several long-term customers expanded their BioKey deployments. Partially offsetting the gains were declines in recurring and non-recurring service revenues. For the nine months ended September 2024, revenues were $5.5 million compared to $5.9 million for the first nine months of 2023, as license fees and hardware gains were more than offset with the loss of large recurring software agreements and one large customization customer from a prior year period. To provide more background, we agreed to exit our civil secure civil agreement in Europe in Q2 as it had proved to be challenging and fairly low-margin business did not justify the resources required. While the termination of the agreement provides some revenue headwind in the near term, this action should substantially benefit our blended gross margin moving forward. Our overall gross profit and gross margin comparisons improved significantly in Q3 2024, primarily due to a $1 million hardware reserve that was taken in Q3 2023, a higher portion of licensee revenue in Q3 2024, lower cost of support deployment, and lower license fees for third-party software included in BioKey's full secure offerings. We trimmed our operating expenses by $46,000 in Q3 2024 versus Q3 2023, due to reductions in headquarters expenses, sales personnel costs, and marketing show expenses, partially offset by an increase in professional services primarily related to the company's financing activities. Also, offsetting lower SG&A costs was a $122,000 increase in research, development, and engineering expense related to personnel to support product development. Reflecting higher revenue and gross profit, and level operating expenses, BioKey's net loss improved to $0.7 million or $0.39 per share in Q3 2024 from a loss of $1.8 million or $3.22 per share in Q3 2023. For the first nine months of 2024, we reduced our net loss to $2.9 million or $1.69 per share versus a net loss of $6.1 million or $10.79 per share in the comparable 2023 period, which included a $2.5 million hardware reserve. We continue to focus on increasing revenue and controlling costs to support our path to cash flow breakeven and profitability. In terms of our balance sheet, the cash position as of September 30, 2024, BioKey had current assets of approximately $4.6 million, including $1.8 million of cash and cash equivalents, $2 million of accounts receivable and due from Factor, $387,000 of inventory, net of reserves, and $383,000 of prepaid expenses and other current assets. Mike mentioned two large customer expansions we expect to benefit our Q4 results and future quarters, and I look forward to updating you on these and other items in our Q4 call. This concludes our prepared remarks. I will ask the operator to prepare for Q&A.
Operator: We will now begin the question and answer session. At this time, we will pause momentarily to assemble our roster. The first question comes from Jack Vander Aarde with Maxim (NASDAQ:MXIM) Group.
Jack Vander Aarde: Okay, great. Good morning, guys. I appreciate the third-quarter update. Thank you for taking my questions, Mike. Great to see the revenue pickup in the third quarter, which I believe is a typically seasonally soft quarter, at least in Europe. I guess some of it probably has to do with that large order that slipped into the third quarter. I think you announced last quarter that there's this large $450,000 order that may have slipped in there, but just give me your thoughts on where the upside was this quarter, and I do think it is typically a weaker quarter.
Mike DePasquale: Yeah. Thank you, Jack. Good morning. Yes, you are absolutely correct. Typically, the Q3 business is softer than any of the other three quarters in the year, mostly again, as you say, because of the international described in my prepared remarks for some existing customers. And so we are seeing a really, really positive trend in the adoption, I will call it the expansion of our solutions in some of our larger customer accounts. And that's a testament to the stickiness and the quality and the value of what we bring to the table. So this was a very productive and a really good quarter for us.
Jack Vander Aarde: Excellent. Well, great to see that. You know, another question, kind of a follow-up, is with regard to a specific order. You press released it as well. It was on September 10th. It was a leading international defense ministry, a $500,000 follow-on order that was announced on September 10th. So did that whole order get recognized in the third quarter? Or just curious there if you have that off the top of your head.
Mike DePasquale: Yes. Okay. So that, yeah, that was recognized in the quarter.
Jack Vander Aarde: Okay. And then this large, much larger order from a long-term financial services customer for $910,000, that came subsequently after the quarter end. So will that all get recognized in the fourth quarter?
Mike DePasquale: Yeah. As I mentioned, first of all, that was not in the third quarter. That was in the fourth quarter, as you are accurate with that. A portion of it, about $250,000 or so, will be recognized in the fourth quarter. And the balance will be in Q1. They are an annual subscription customer, and they doubled the size of their deployment. So their annual subscription, I believe, renews in February. So now that will be part of their newer and updated subscription starting next year. So about $250,000 this quarter and the $650,000, whatever in round numbers, in Q1.
Jack Vander Aarde: Okay. Fantastic. And then are you implying that there are further orders related to that customer after the renewal in February? Or is this a part of that?
Mike DePasquale: No. There will be additional opportunities and expansion, but their annual now recurring revenue contract size will be in the $1.4 million range, so significant. That will be one of our larger subscription contracts.
Jack Vander Aarde: Okay. Great. I appreciate the color there. That's great to hear. And then questions, just a couple of questions on the outlook, and then I'll hop back in the queue. But so you expect 2024 revenue to meet or exceed 2023 revenue of $7.75 million. So this implies, it looks like, you expect at least Q4 revenue of at least $2.3 million at a minimum, basically, which is above where I was. So that's good to see. Do you expect the fourth-quarter revenue to be mostly license revenue similar to the third quarter?
Mike DePasquale: Yes. Yes, we do. Okay. Yes, and we expect to have a good solid Q4.
Jack Vander Aarde: Yes. Okay. Great. And you know, and maybe a question for Cece as well if she wants to chime in here. The operating expenses in the third quarter, it looks like all in almost $2.3 million. So a nice kind of reduction from the prior two quarters. So it looks like you have been pretty effective with cutting some costs here. Is this a good baseline looking at the I can't quite recall. Is the fourth quarter, is there a seasonal uptick in OpEx at all, or is this a good run rate going forward?
Ceci Welch: It's a fairly good run rate. We've done some, as we've said, some financing, so it's a little heavy right now. So we are looking long-term to just cut some of those types of expenses. But I would say, you know, the $2.3 million is a good number or less, obviously.
Jack Vander Aarde: Okay. That's very helpful. So that sets you up, that sets you guys up for a fairly reasonable breakeven revenue target, I imagine, as we move forward here in 2025. You know, Mike, with your license installed base and subscription installed base kind of ramping up here, it has been ramping up. Do you feel like you're at the point or getting close to the point where you have enough visibility just to kind of introduce formal guidance at some point? I'm just curious to get your thoughts on when you might, what needs to happen for you to have that level of visibility and confidence? Thanks.
Mike DePasquale: I think as we get into 2025, I think we will be able to do that. You can see that more and more of our business is subscription. We have really migrated, especially the PortalGuard base, where we're getting we have visibility into some larger opportunities. And I think we're getting close there. I think we're also, look, our goal and objective, obviously, Cece and I, want to get this company to breakeven into profitability. We're moving very aggressively in that direction right now. So I hope that we'll be able to do that as we get into 2025, Jack.
Jack Vander Aarde: Okay. Great to hear. Well, I guess that's all the questions I have for you. I appreciate the time, and good luck. Record a cracking story.
Mike DePasquale: Thank you. Our next question comes from Dan Kamas, a Private Investor. Please go ahead.
Dan Kamas: Hey, guys. Good quarter. I'm wondering about do you have any kind of estimate for the recurring revenues you expect from the Defense Ministry going forward?
Mike DePasquale: The Defense Ministry is not subscription revenue. They are still our, I'll call it, one of our larger perpetual customers. We do have a subscription element in the agreement, but it's for support and maintenance. But the Defense Ministry is just continuing to expand. We're up to 33,000 or so users now. There's a long, long way to go. A lot of runways ahead there. So that business is going to continue to be significant over the coming two to three years, and it'll be in the ranges that we've seen in the past, right, where typically spent somewhere between a million or so, a million to a million and a half a year, sometimes more, sometimes a little bit less.
Dan Kamas: I see. What's the maintenance on that? Is that, like, ten percent?
Mike DePasquale: Well, it's for support. So it's for support. Dollar-wise, I can't say it's dependent on the user count. Right? So it's generally at twenty percent of the typical contract value of the software.
Dan Kamas: Is there any recurring revenue on the British Columbia deal or is that also a subscription?
Mike DePasquale: No. That's a subscription.
Dan Kamas: Is there any estimate on the recurring revenue on that?
Mike DePasquale: Yes. It's a subscription, yes.
Dan Kamas: No, no. But how much recurring revenue do you expect?
Mike DePasquale: Oh, I don't. Dan, I don't know. Okay. I don't have that off the top of my head. I don't know how I don't even know the size of that order, quite frankly.
Dan Kamas: You mentioned that the improvement, I mean, the gross margins were pretty high as was related to the hardware reserve. Does that mean that you sold some of the old hardware inventory that was reserved?
Mike DePasquale: We have. And we continue to sell the hardware, and we expect to see more significant orders for that this quarter and beyond. So the answer to that question is yes. But also, we're very, very focused on higher-margin licensed sales. And we're also, we've been razor-focused on, especially in our European operation, we had a large software maintenance agreement that was negligible in the context of margins. And we decided not to renew that agreement. So it's going to have a very positive impact on our overall blended gross margins. It's giving us an opportunity to focus more, especially with our resources, on the biokinetics products that are much higher gross margins, which are in the, our software is in the 80%, 90% range. So that's another reason why you're seeing an increase in the gross margin. So overall, this is going to have a much, much better impact on our financials, and it's going to create a shorter pathway to getting to breakeven and profitability.
Dan Kamas: I see. Well, I think that's good news. Are you saying that these kind of gross margins you expect to continue?
Mike DePasquale: Yes. And we've been exclusive of the write-down, especially over the last year, year and a half on the hardware, our gross margins have been in that range. They've been in the 70s. We've been holding in that range, and we expect that to absolutely continue.
Dan Kamas: Okay. Can you give some kind of number to how much hardware you sold in the third quarter?
Mike DePasquale: Cece, I think you can.
Ceci Welch: We reduced the inventory by about $100,000 just last quarter. We expect at least double or a lot bigger based on the contract that we expect to come in this quarter.
Mike DePasquale: Well, we've already sold some this quarter, and we have again. Yes, and I think I've spoken to this openly. We've been waiting on a very large order for a significant project, and it appears that that is going to happen this quarter. So we're thinking this is pretty positive for us. As you know, we've written down the entire inventory, and so it's all cash, and it all goes to the bottom line. It's a very, very positive impact on the financials.
Dan Kamas: Yeah. Absolutely. This is in Africa, is it?
Mike DePasquale: You mean is the project in Africa?
Dan Kamas: Yeah. It's an international project.
Ceci Welch: So I think, yes, at least $2.4 million in the fourth quarter.
Dan Kamas: And you said that was mostly licensing. Right? I think you answered that question already.
Mike DePasquale: Yeah. And it'll be, and some of this hardware as well, which again carries even a higher margin than the software.
Dan Kamas: I see. Yeah. Absolutely. Right. I mean, it's Yes. Yes.
Mike DePasquale: Yeah.
Dan Kamas: How much in one-time financial costs are you gonna have in the fourth quarter? And will that be the end of it? Or are they done already? From the financings and
Mike DePasquale: I'm not sure I understand that. I think what Cece was saying is SG&A expense, meaning legal and interest, that kind of thing. Is that what you're referencing?
Dan Kamas: No, I'm talking about I think you did a, you raised capital with a loan, and then you had to warrant. I'm just wondering if there's the one-time cost there that you'll be taking the fourth quarter.
Ceci Welch: We are always working on things, so I expect it to continue, but not at the rate it's been.
Dan Kamas: I'm saying that they're usually financing costs, right, associated with the warrants and the loans, and I'm just wondering what those costs are. Just find it. The one-time cost. For the financings.
Ceci Welch: Well, for the first three quarters, it's been close to probably $200,000 between auditors and legal folks.
Dan Kamas: Okay. Were there any costs to the I think you did the warrants in the fourth quarter in October, right? So are there any significant costs, financing costs for that warrant deal?
Ceci Welch: So we had some associated costs to that, of course. Yes.
Dan Kamas: Just trying to get a feel for how much? If you can.
Mike DePasquale: Also, by the way, I think the warrant is due was done in the third quarter, if I'm not mistaken. Cece, wasn't that September?
Dan Kamas: Yes, it was.
Mike DePasquale: That was the third quarter, Dan. So it's already disclosed in
Dan Kamas: Oh, okay. My mistake. Sorry. Yeah. Got it.
Mike DePasquale: No. It's already disclosed. It's already there.
Dan Kamas: So then shouldn't be too much for the fourth quarter then.
Mike DePasquale: Well, I think that's what Cece is intimating.
Dan Kamas: I see. I got it. Okay. Got it. This, okay. So you exited the civil service market. That's you're talking about the European operations. Right?
Ceci Welch: Yeah. When you say civil service, I didn't
Mike DePasquale: No. No. No. I said services agreement. We had a service or support agreement with Swivel Secure Limited. And that agreement again was, we really put that in place to be able to support, have a little more control over support of the product. But, again, with the amount of resources that were required and the margins on the contract, it just didn't make any sense for us to continue.
Dan Kamas: Did that change your relationship with Swivel? Or I'm not quite sure. Is this BioKey personnel that were
Mike DePasquale: No. No. I mean, we always had, remember, we have a reseller agreement. We had a reseller agreement in place with Swivel. Where the margins on what we sold out of that product in the European markets was 50%. Our own products obviously carry a higher gross margin. It was always our goal, right, over time, we negotiated that contract about two years ago. Ultimately morph those customers into the PortalGuard solution, which is a much higher margin product. And so this is kind of a, I'll call it the evolution of that business arrangement. And again, it just didn't make any sense anymore. For the thin margins to continue to operate with that agreement. Just pretty straightforward.
Dan Kamas: Alright. So your accounts receivable are at $1.9 million. I know that's pretty large. When do you expect to be able to collect those sums?
Ceci Welch: We've collected the majority of it. We just happen to ship a lot of things in September. So but most of it's been collected already.
Dan Kamas: In the fourth quarter?
Ceci Welch: Go ahead.
Dan Kamas: Okay. Good. Alright. Well, it sounds good, guys. Thank you.
Mike DePasquale: You're welcome. Thanks, Dan.
Operator: At this time, showing no further questions. I'll ask Mike DePasquale for closing remarks.
Mike DePasquale: Thank you, everyone, and thank you for taking the time to join our call today. Look for us at the Gartner IAM conference in December. And as always, we'll continue to update you via regular press releases. Feel free to reach out to our IR team whose contact information is listed in our press release if you have any questions regarding this call or any other items. Thank you very much, and have a great day and a great weekend.
Operator: The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.